Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Russell

Showing results (1091-1100 of 1,120) with videos related to

Pageof 112
Sort By:
Avian Pathology : Journal of the W.V.P.A|July 1, 1985
Antigenic and biological characterisation of avian paramyxovirus type I isolates from pigeons--an international collaborative studyD J Alexander, P H Russell, G Parsons, et al.
Haematologica|December 9, 2017
Melphalan 140 mg/m<sup>2</sup> or 200 mg/m<sup>2</sup> for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working PartyHolger W Auner, Simona Iacobelli, Giulia Sbianchi, et al.
British Journal of Haematology|July 14, 2020
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trialGraham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 7, 2016
Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant ResearchVictoria T Potter, Simona Iacobelli, Anja van Biezen, et al.
Blood|May 1, 2024
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AMLJad Othman, Nicola Potter, Adam Ivey, et al.
Plos Medicine|January 11, 2021
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trialGraham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
Nature Communications|August 8, 2022
Unified classification and risk-stratification in Acute Myeloid LeukemiaYanis Tazi, Juan E Arango-Ossa, Yangyu Zhou, et al.
Haematologica|June 6, 2020
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Blood|November 14, 2025
CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18Steven Knapper, Laura W Dillon, Malavika Babu, et al.
Genome Research|September 15, 2022
The western redcedar genome reveals low genetic diversity in a self-compatible coniferTal J Shalev, Omnia Gamal El-Dien, Macaire M S Yuen, et al.
Pageof 112

Showing results (1091-1100 of 1,120) with videos related to

Sort By:
Pageof 112
Avian Pathology : Journal of the W.V.P.A|July 1, 1985
Antigenic and biological characterisation of avian paramyxovirus type I isolates from pigeons--an international collaborative studyD J Alexander, P H Russell, G Parsons, et al.
Haematologica|December 9, 2017
Melphalan 140 mg/m<sup>2</sup> or 200 mg/m<sup>2</sup> for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working PartyHolger W Auner, Simona Iacobelli, Giulia Sbianchi, et al.
British Journal of Haematology|July 14, 2020
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trialGraham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 7, 2016
Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant ResearchVictoria T Potter, Simona Iacobelli, Anja van Biezen, et al.
Blood|May 1, 2024
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AMLJad Othman, Nicola Potter, Adam Ivey, et al.
Plos Medicine|January 11, 2021
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trialGraham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
Nature Communications|August 8, 2022
Unified classification and risk-stratification in Acute Myeloid LeukemiaYanis Tazi, Juan E Arango-Ossa, Yangyu Zhou, et al.
Haematologica|June 6, 2020
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Blood|November 14, 2025
CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18Steven Knapper, Laura W Dillon, Malavika Babu, et al.
Genome Research|September 15, 2022
The western redcedar genome reveals low genetic diversity in a self-compatible coniferTal J Shalev, Omnia Gamal El-Dien, Macaire M S Yuen, et al.
Pageof 112